Newstral
Sarepta Therapeutics Inc
- ISarepta Therapeutics receives expanded approval for Elevidysinvezz.com
- TThe Sarepta Therapeutics Pipeline No One is Talking Aboutthestreet.com
- LGlobal Dystrophin Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Asklepios BioPharmaceutical Inc, Sarepta Therapeutics Inc, Editas Medicine Inc, BioMarin Pharmaceut…liverpoolstudentmedia.com
- LDystrophin Market 2021-2026 Size and Share, Recent Enhancements and Regional Analysis | Key Companies: Asklepios BioPharmaceutical Inc, Sarepta Therapeutics Inc, Editas Medicine Inc, BioMarin Pharm…liverpoolstudentmedia.com
- LGlobal Lysosomal Alpha Glucosidase Market 2021: SWOT Analysis of Key Driving Factors for Growing CAGR Value | Top Brands: Amicus Therapeutics Inc, Audentes Therapeutics Inc, Etubics Corp, Genzyme C…liverpoolstudentmedia.com
- MSarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drugmarketwatch.com
- MSarepta stock falls on FDA concerns about drugmarketwatch.com
- MSarepta stock drops on erroneous adverse event report to FDAmarketwatch.com
- MSarepta stock up 3% after announcing acquisition of gene-therapy company Myonexusmarketwatch.com
- MSarepta stock rises after FDA lifts clinical hold on gene therapy programmarketwatch.com
- MSarepta expected, but is disappointed by European regulators decision on DMD treatmentmarketwatch.com
- MPfizer stops developing therapy for the rare disease Duchenne muscular dystrophymarketwatch.com
- MSarepta stock drops after Muscular Dystrophy study halted by FDAmarketwatch.com
Sarepta Gets Boost From Early Trial Results on Muscular Dystrophy Treatmentwsj.com
- MSarepta shares rocket 55% on positive early results for DMD gene therapymarketwatch.com
- MSarepta receives negative opinion in Europe for treatment for Duchenne muscular dystrophymarketwatch.com
- MSolid Biosciences shares crater 63% on clinical hold for lead productmarketwatch.com
- MSarepta Therapeutics plans NDA of Duchenne MD treatment by year endmarketwatch.com
- MSarepta shares drop 2% despite Q4 profit, revenue beatsmarketwatch.com
- MNot even Solid Biosciences’ latest disclosure could sour its market debutmarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.